Shots:
BioNTech reported that its P-II/III AHEAD-MERIT study did not meet the first dual 1EP of progression-free survival (PFS) for BNT113 plus pembrolizumab vs pembrolizumab alone in 1L treatment of unresectable recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC) expressing PD-L1
The Independent Data Monitoring Committee recommended continuing the study to evaluate…
